卵巢癌腹水来源微囊体促进卵巢癌SKOV3细胞增殖和耐药-东南大学学报医学版

卵巢癌腹水来源微囊体促进卵巢癌SKOV3细胞增殖和耐药

单位：1. 南京医科大学附属南京医院(南京市第一医院)妇科, 江苏南京 210006;
2. 南京医科大学附属南京医院(南京市第一医院)中心实验室, 江苏南京 210006

分类号：R737.31

出版年·卷·期（页码）：2016·35·第一期（71-75）

摘要：

目的:通过检测卵巢癌患者腹水来源的微囊体(MVs)体外促进人卵巢癌细胞株增殖及对顺铂的药物耐受作用,探讨腹水MVs对卵巢癌发生发展及治疗的影响。方法:采用超速离心法分离获得6例恶性卵巢癌腹水中的MVs,在体外观察MVs对卵巢癌细胞SKOV3增殖的影响,并观察不同MVs浓度下SKOV3细胞株对顺铂细胞毒性的耐药效果。结果:成功从卵巢癌腹水中获得了MVs,加入MVs组与对照组相比,能明显促进SKOV3细胞的增殖(P<0.05),且呈一定的浓度依耐性。一定浓度的MVs可以抑制低浓度的顺铂的细胞毒性(P<0.05),当药物浓度增大(顺铂10μg·ml^-1,紫杉醇10μg·ml^-1)MVs的抑制作用没有意义(P>0.05)。结论:卵巢癌腹水来源的MVs能明显促进卵巢癌细胞的增殖,并在卵巢癌细胞对低浓度的顺铂药物耐受中起促进作用,为临床卵巢癌治疗过程中腹水MVs的检测提供新的临床意义。

Objective:To extract the microvesicles from the ascites of patients with ovarian cancer and explore the proliferation effect on SKOV3 cell lines or toxicity. Methods:The microvesicles from the ascites were got by using the ultracentrifugation. The proliferation effects of SKOV3 cell lines was observed. The cell survival proportion when exposed to cis-platinum in different concentration of microvesicles was paid attention to. Results:We succeeded in acquiring the microvesicles. The SKOV3 cell lines exposed to microvesicles showed significant proliferation effect, which depended on the concentration to some extent. A low concentration of microvesicles could protect the toxicity from the cis-platinum (P<0.05), but not any significance was observed when the concentration was getting high. Conclusion:The microvesicles from the ascites of patients with ovarian cancer can stimulate the proliferation of SKOV3 cell lines in vitro and help resist the cell toxicity effect of cis-platinum in a low concentration, which sheds lights into the therapy of ovarian cancer especially the patiens with ascites.

参考文献：

[1] LIANG B,PENG P,CHEN S,et al.Characterization and proteomic analysis of ovarian cancer-derived exosomes[J].Mol Cancer,2013,80(2):171-182.
[2] SHENDER V O,PAVLYUKOV M S,ZIGANSHIN R H,et al.Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication[J].Mol Cancer,2014,13(4):355-357.
[3] CHEVILLET J R,KANG Q,RUF I K,et al.Quantitative and stoichiometric analysis of the microRNA content of exosomes[J].Eur J Pharmacol,2013,80(2):17-23.
[4] CAPPELLESSO R,TINAZZI A,GIURICI T,et al.Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions[J].Cancer Cytopathol,2014,122(9):685-693.
[5] FUJITA Y,KUWANO K,OCHIYA T,et al.The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research[J].Biomed Res Int,2014,20(14):1-8.
[6] LI J,ZHANG Y,LIU Y,et al.Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis[J].J Biol Chem,2013,288(32):23586-23596.
[7] JAISWAL R,LUK F,GONG J,et al.Microparticle conferred microRNA profiles——implications in the transfer and dominance of cancer traits[J].Mol Cancer,2012,11(2):37-44.
[8] COLOMBO M,RAPOSO G,THERY C.Biogenesis,secretion,and intercellular interactions of exosomes and other extracellular vesicles[J].Annu Rev Cell Dev Biol,2014,30(4):255-289.
[9] YAMADA N,TSUJIMURA N,KUMAZAKI M,et al.Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells[J].Biochim Biophys Acta,2014,1839(11):1256-1272.
[10] GIUSTI I,D ASCENZO S,DOLO V.Microvesicles as potential ovarian cancer biomarkers[J].Biomed Res Int,2013,20(13):1-12.
[11] PASCUCCI L,COCCÈ V,BONOMI A,et al.Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth:A new approach for drug delivery[J].J Control Release,2014,192(11):262-270.
[12] GONG J,LUK F,JAISWAL R,et al.Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance[J].Eur J Pharmacol,2013,721(13):116-125.
[13] van DOMMELEN S M,VADER P,LAKHAL S,et al.Microvesicles and exosomes:Opportunities for cell-derived membrane vesicles in drug delivery[J].J Control Release,2012,161(2):635-644.
[14] JOHNSEN K B,GUDBERGSSON J M,SKOV M N,et al.A comprehensive overview of exosomes as drug delivery vehicles-Endogenous nanocarriers for targeted cancer therapy[J].Biochim Biophys Acta,2014,1846(1):75-87.
[15] 刘梦娜,谢静燕,赵树立.雌激素受体在卵巢癌研究中的进展[J].东南大学学报:医学版,2014,33(2):215-218.
[16] 赵一兵,吴强,曲军卫,等.卵巢癌肿瘤细胞减灭术的危险因素分析[J].东南大学学报:医学版,2014,33(6):696-698.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录